Expertise in

conditions

Eugenio M. Mercuri

Rome, IT

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

Rome, IT

Overview

Eugenio Mercuri practices in Rome, Italy. Mr. Mercuri is highly rated in 23 conditions, according to our data. His top areas of expertise are Primary Lateral Sclerosis, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Spinal Muscular Atrophy (SMA).

His clinical research consists of co-authoring 481 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Rome, Italy

Other Locations

Milan, Italy

Pisa, Italy

Policlinico Gemelli, Italy

Messina, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies

Enrollment Status: Recruiting

Publish Date: January 21, 2026

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2

Enrollment Status: Completed

Publish Date: January 26, 2026

Intervention Type: Biological

Study Drug: Onasemnogene Abeparvovec-Xioi

Study Phase: Phase 3

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy

Enrollment Status: Completed

Publish Date: November 18, 2025

Intervention Type: Drug

Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment

Study Phase: Phase 3

Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care

Enrollment Status: Active_not_recruiting

Publish Date: March 14, 2025

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

Enrollment Status: Terminated

Publish Date: August 26, 2024

Intervention Type: Drug

Study Drug: Pamrevlumab

Study Phase: Phase 3

A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Enrollment Status: Terminated

Publish Date: March 12, 2024

Intervention Type: Drug

Study Drug: Pamrevlumab

Study Phase: Phase 3

Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Enrollment Status: Completed

Publish Date: February 02, 2023

Intervention Type: Drug

Study Drug: Givinostat

Study Phase: Phase 3

An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Enrollment Status: Completed

Publish Date: December 09, 2021

Intervention Type: Drug

Study Phase: Phase 2

A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids

Enrollment Status: Terminated

Publish Date: December 03, 2021

Intervention Type: Drug

Study Drug: Idebenone

Study Phase: Phase 3

A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study

Enrollment Status: Terminated

Publish Date: December 03, 2021

Intervention Type: Drug

Study Drug: Idebenone

Study Phase: Phase 3

A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

Enrollment Status: Terminated

Publish Date: May 20, 2021

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

View 10 Less Clinical Trials

481 Total Publications

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.

Journal: Expert review of neurotherapeutics

Published: November 13, 2025

View All 481 Publications

Frequently Asked Questions about Eugenio M. Mercuri

Is Eugenio M. Mercuri a top-rated expert for Primary Lateral Sclerosis?

MediFind is an objective health platform that identifies experts based on real-world data. Eugenio M. Mercuri is classified as an Elite expert for Primary Lateral Sclerosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eugenio M. Mercuri participate in research or clinical trials?

Yes. Eugenio M. Mercuri has published 481 articles and abstracts on conditions like Primary Lateral Sclerosis. You can view a list of Eugenio M. Mercuri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mercuri's expertise for a condition

ConditionClose